Mid-point of patient enrolment reached in AIPAC trial
Filed with ASX · · 2 pages · English
In the deck
Story so far
Earlier from Immutep
- Webcast slides for TACTI-mel clinical trial data
- Response to ASX Price Query
- Immutep raises A$6.85M through institutional placement
- US patent grant for IMP701 antibody
- Immutep receives A$686,704 R&D Tax Incentive
Later from Immutep
- Immutep submits IND application with FDA
- Immutep receives IND approval from US FDA for IMP321
- TACTI-mel Patient Recruitment Complete & Operational Update
- Appendix 4E & 2018 Full Year Statutory Accounts
- Progress towards clinical development of IMP761
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep